Liquidia (NASDAQ:LQDA) Now Covered by Analysts at Lifesci Capital

Lifesci Capital began coverage on shares of Liquidia (NASDAQ:LQDA) in a report published on Thursday, Benzinga reports. The firm issued an outperform rating and a $30.00 price objective on the stock.

A number of other analysts also recently weighed in on the stock. Needham & Company LLC reaffirmed a buy rating and set a $25.00 price target on shares of Liquidia in a report on Monday, August 19th. Raymond James upgraded Liquidia from an outperform rating to a strong-buy rating in a research note on Monday, August 19th. BTIG Research dropped their price objective on Liquidia from $29.00 to $25.00 and set a buy rating for the company in a research report on Monday, August 19th. HC Wainwright decreased their target price on Liquidia from $32.00 to $29.00 and set a buy rating on the stock in a research report on Tuesday, August 20th. Finally, Oppenheimer assumed coverage on shares of Liquidia in a report on Tuesday, June 25th. They issued a market perform rating for the company. One analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, Liquidia presently has a consensus rating of Moderate Buy and an average price target of $24.00.

Liquidia Price Performance

LQDA stock opened at $10.03 on Thursday. The business’s fifty day moving average price is $10.44 and its two-hundred day moving average price is $12.19. The stock has a market capitalization of $766.43 million, a price-to-earnings ratio of -6.43 and a beta of 0.22. Liquidia has a fifty-two week low of $5.71 and a fifty-two week high of $16.99.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.02). Liquidia had a negative return on equity of 183.57% and a negative net margin of 755.46%. The business had revenue of $3.66 million during the quarter, compared to analyst estimates of $7.92 million. Research analysts expect that Liquidia will post -1.71 EPS for the current year.

Insider Buying and Selling at Liquidia

In other news, Director Caligan Partners Lp acquired 150,000 shares of Liquidia stock in a transaction dated Friday, August 30th. The shares were bought at an average cost of $9.51 per share, with a total value of $1,426,500.00. Following the purchase, the director now owns 6,994,997 shares in the company, valued at $66,522,421.47. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, CFO Michael Kaseta sold 3,906 shares of the firm’s stock in a transaction that occurred on Friday, July 12th. The stock was sold at an average price of $12.53, for a total transaction of $48,942.18. Following the completion of the sale, the chief financial officer now owns 312,389 shares of the company’s stock, valued at $3,914,234.17. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Caligan Partners Lp purchased 150,000 shares of Liquidia stock in a transaction on Friday, August 30th. The stock was bought at an average price of $9.51 per share, with a total value of $1,426,500.00. Following the completion of the acquisition, the director now directly owns 6,994,997 shares of the company’s stock, valued at approximately $66,522,421.47. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders sold 21,422 shares of company stock valued at $256,998. 31.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Liquidia

Several institutional investors have recently made changes to their positions in LQDA. Quest Partners LLC bought a new stake in Liquidia in the 2nd quarter valued at about $27,000. Hilltop National Bank bought a new stake in Liquidia during the 2nd quarter valued at $33,000. Whitcomb & Hess Inc. raised its holdings in Liquidia by 10.2% during the third quarter. Whitcomb & Hess Inc. now owns 11,599 shares of the company’s stock worth $116,000 after buying an additional 1,074 shares during the last quarter. Deuterium Capital Management LLC bought a new position in shares of Liquidia in the second quarter valued at $120,000. Finally, DMC Group LLC acquired a new position in shares of Liquidia during the second quarter valued at about $122,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).